{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-014403","form_type":"8-K","ticker":null,"cik":"0001850838","company_name":"Omega Therapeutics, Inc.","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.298400+00:00","generated_at":"2026-05-27T08:28:28.509705+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Two Omega directors resign; Jeffrey Varsalone appointed to board","bullets":["Ravi Mehrotra and Robert Rosiello resigned from the board effective January 22, 2025.","Board appointed Jeffrey Varsalone as Class I director effective January 24, 2025; monthly cash fee of $30,000.","Richard Kender moved from Class III to Class II director to rebalance board classes.","Board now consists of two directors per class (I, II, III)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-014403","json":"https://secwatch.observer/filing/0001193125-25-014403.json","markdown":"https://secwatch.observer/filing/0001193125-25-014403.md","text":"https://secwatch.observer/filing/0001193125-25-014403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/0001193125-25-014403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/d893135d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:28:28.509705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2abe104035","claim":"Jeffrey T. Varsalone was appointed as Class I Director at Omega Therapeutics, Inc..","evidence_excerpt":"On January 24, 2025, the Board appointed Jeffrey T. Varsalone as a Class I director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/0001193125-25-014403-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"b8c22f451a","claim":"Robert L. Rosiello resigned as Class I Director at Omega Therapeutics, Inc..","evidence_excerpt":"On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello each submitted their resignation as a member of the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/0001193125-25-014403-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"e3511316c5","claim":"Ravi Mehrotra resigned as Class I Director at Omega Therapeutics, Inc..","evidence_excerpt":"On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello each submitted their resignation as a member of the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/0001193125-25-014403-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}